1
|
Pintaningrum Y, Humaera NN, Rafiq A, Tanti A. OR10. Association between heart functional capacity with depression severity on patient with coronary artery disease. Eur Heart J Suppl 2021. [DOI: 10.1093/eurheartjsupp/suab122.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
Aims
Coronary artery disease has become the main factor of heart failure. Current research has shown association between heart failure with depression. However even before the heart failure, patient with coronary artery diseases may have depression. This study aims to investigate the correlation between heart functional capacity based on new york heart association scale with presence and severity of depression in patient with coronary artery disease.
Methods and Results
50 Patients diagnosed with coronary artery diseases who agree to participate completes patient health questionnaire-9. Patient’s coronary artery disease severity determined by patient functional heart based on capacity new york heart association. Chi square test used to find correlation.
Discussion
Based on chi-square methods (sig new york heart association: 0.014, patient health questionnaire: 0.021) p < 0.05, there is a strong correlation between functional heart capacity based on new york heart association assessment with presence and severity of depression in patient with coronary artery diseases. It shows the correlation not only found in heart failure patient and the depression confirmed in coronary artery disease patients at Nusa Tenggara Province Hospital using patient health questionnaire-9.
Collapse
Affiliation(s)
- Y Pintaningrum
- Faculty of Medicine, Universitas Mataram , Nusa Tenggara Barat, Indonesia
| | - N N Humaera
- Faculty of Medicine, Universitas Mataram , Nusa Tenggara Barat, Indonesia
| | - A Rafiq
- Faculty of Medicine, Universitas Mataram , Nusa Tenggara Barat, Indonesia
| | - A Tanti
- Faculty of Medicine, Universitas Mataram , Nusa Tenggara Barat, Indonesia
| |
Collapse
|
2
|
Tanti A, Serracino-Inglott A, Borg JJ. Designing a national combined reporting form for adverse drug reactions and medication errors. East Mediterr Health J 2015; 21:246-55. [PMID: 26077519 DOI: 10.26719/2015.21.4.246] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/03/2014] [Accepted: 01/28/2015] [Indexed: 11/09/2022]
Abstract
The Maltese Medicines Authority was tasked with developing a reporting form that captures high-quality case information on adverse drug reactions (ADRs) and medication errors in order to fulfil its public-health obligations set by the European Union (EU) legislation on pharmacovigilance. This paper describes the process of introducing the first combined ADR/medication error reporting form in the EU for health-care professionals, the analysis of reports generated by it and the promotion of the system. A review of existing ADR forms was carried out and recommendations from the European Medicines Agency and World Health Organization audits integrated. A new, combined ADR/medication error reporting form was developed and pilot tested based on case studies. The Authority's quality system (ISO 9001 certified) was redesigned and a promotion strategy was deployed. The process used in Malta can be useful for countries that need to develop systems relative to ADR/medication error reporting and to improve the quality of data capture within their systems.
Collapse
Affiliation(s)
- A Tanti
- Medicines Authority, Gzira, Malta
| | - A Serracino-Inglott
- Medicines Authority, Gzira, Malta.,Department of Pharmacy, University of Malta, Msida, Malta
| | - J J Borg
- Medicines Authority, Gzira, Malta.,Department of Biology, School of Pharmacy, University of Tor Vergata, Rome, Italy.
| |
Collapse
|
3
|
Surget A, Tanti A, Leonardo ED, Laugeray A, Rainer Q, Touma C, Palme R, Griebel G, Ibarguen-Vargas Y, Hen R, Belzung C. Antidepressants recruit new neurons to improve stress response regulation. Mol Psychiatry 2011; 16:1177-88. [PMID: 21537331 PMCID: PMC3223314 DOI: 10.1038/mp.2011.48] [Citation(s) in RCA: 359] [Impact Index Per Article: 27.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Recent research suggests an involvement of hippocampal neurogenesis in behavioral effects of antidepressants. However, the precise mechanisms through which newborn granule neurons might influence the antidepressant response remain elusive. Here, we demonstrate that unpredictable chronic mild stress in mice not only reduces hippocampal neurogenesis, but also dampens the relationship between hippocampus and the main stress hormone system, the hypothalamo-pituitary-adrenal (HPA) axis. Moreover, this relationship is restored by treatment with the antidepressant fluoxetine, in a neurogenesis-dependent manner. Specifically, chronic stress severely impairs HPA axis activity, the ability of hippocampus to modulate downstream brain areas involved in the stress response, the sensitivity of the hippocampal granule cell network to novelty/glucocorticoid effects and the hippocampus-dependent negative feedback of the HPA axis. Remarkably, we revealed that, although ablation of hippocampal neurogenesis alone does not impair HPA axis activity, the ability of fluoxetine to restore hippocampal regulation of the HPA axis under chronic stress conditions, occurs only in the presence of an intact neurogenic niche. These findings provide a mechanistic framework for understanding how adult-generated new neurons influence the response to antidepressants. We suggest that newly generated neurons may facilitate stress integration and that, during chronic stress or depression, enhancing neurogenesis enables a dysfunctional hippocampus to restore the central control on stress response systems, then allowing recovery.
Collapse
Affiliation(s)
- A Surget
- U930 Imaging and Brain, Inserm, Tours, France.
| | - A Tanti
- U930 Imaging and Brain, Inserm, Tours, France,Université François Rabelais, Tours, France
| | - E D Leonardo
- Departments of Psychiatry and Neuroscience, Columbia University, New York, NY, USA
| | - A Laugeray
- U930 Imaging and Brain, Inserm, Tours, France,Université François Rabelais, Tours, France
| | - Q Rainer
- U930 Imaging and Brain, Inserm, Tours, France,Université François Rabelais, Tours, France
| | - C Touma
- Research Group of Psychoneuroendocrinology, Max Planck Institute of Psychiatry, Munich, Germany
| | - R Palme
- Department of Biomedical Sciences/Biochemistry, University of Veterinary Medicine, Vienna, Austria
| | - G Griebel
- Exploratory Unit, Sanofi-Aventis, Chilly-Mazarin, France
| | - Y Ibarguen-Vargas
- U930 Imaging and Brain, Inserm, Tours, France,Université François Rabelais, Tours, France,Kavli Institute for Systems Neuroscience & Centre for the Biology of Memory, Norwegian University of Science and Technology (NTNU), Trondheim, Norway
| | - R Hen
- Departments of Psychiatry and Neuroscience, Columbia University, New York, NY, USA
| | - C Belzung
- U930 Imaging and Brain, Inserm, Tours, France,Université François Rabelais, Tours, France
| |
Collapse
|
4
|
Abstract
Research on depression and antidepressant drugs is necessary, as many patients display poor response to therapy. Different symptomatic and pathophysiological features have been proposed as end points of the depressive phenotype and of the antidepressant action, including anhedonia, depressed mood, alterations in morphology and activity of some brain areas (amygdala, nucleus accumbens, hippocampus, prefrontal cortex and cingulate cortex), modifications in the connectivity between brain structures, changes in neurotransmitters (serotonin, noradrenaline, glutamate and neuropeptides), brain plasticity (neurogenesis, neurotrophins) and abnormal function of the hypothalamic-pituitary adrenal axis. However, few models have been proposed to describe how these end points could induce the depressive phenotype and are involved in the mechanism of action of antidepressants. Here we propose a connectionist-inspired network of depression and antidepressant action, in which the different aetiological factors participating in the release of a depressive episode are represented by input nodes, the different symptomatic as well as pathophysiological end points are represented by an intermediate layer, and the onset of depression or of comorbid disease is represented by the output node. The occurrence of depression and the mechanism of the antidepressant action thus depend upon the weight of the interactions between the different end points, none of them being per se crucial to the onset of a depressive phenotype or to the antidepressant action. This model is heuristic to draw future lines of research concerning new antidepressant therapies, designing new animal models of depression and for a better understanding of the depressive pathology and of its comorbid pathology such as anxiety disorders.
Collapse
Affiliation(s)
- A Tanti
- INSERM U-930, Université François Rabelais Tours, UFR Sciences et Techniques, Parc Grandmont, Tours, France
| | | |
Collapse
|